Skip to main content
. 2023 May 30;16:17562848231174953. doi: 10.1177/17562848231174953

Figure 3.

Figure 3.

Clinical remission rates at weeks 104 and 156, among CD patients (n = 53) with a clinical response or remission at 12 weeks after the initiation of VDZ treatment. Missing data and discontinuation of VDZ were assumed to represent treatment failure.

CD, Crohn’s disease; VDZ, vedolizumab.